Virus-directed, Enzyme Prodrug Therapy with Nitroimidazole Reductase: A Phase I and Pharmacokinetic Study of its Prodrug, CB1954
<p style="text-align:justify;">CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide] is converted by the bacterial enzyme nitroimidazole reductase (NTR) into a potent cytotoxic bifunctional alkylating agent, which can be delivered to tumors in adenoviral vectors as virus-directed, enzyme p...
Main Authors: | Chung-Faye, G, Palmer, D, Anderson, D, Clark, J, Downes, M, Baddeley, J, Hussain, S, Murray, P, Searle, P, Seymour, L, Harris, P, Ferry, D, Kerr, D |
---|---|
Format: | Journal article |
Published: |
American Association for Cancer Research
2001
|
Similar Items
-
The nitroreductase/CB1954 enzyme-prodrug system.
by: Green, N, et al.
Published: (2004) -
Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil.
by: Palmer, D, et al.
Published: (2003) -
Structure and Dynamics of Three <i>Escherichia coli</i> NfsB Nitro-Reductase Mutants Selected for Enhanced Activity with the Cancer Prodrug CB1954
by: Martin A. Day, et al.
Published: (2023-03-01) -
Enhanced efficacy of Escherichia coli nitroreductase/CB1954 prodrug activation gene therapy using an E1B-55K-deleted oncolytic adenovirus vector.
by: Chen, M, et al.
Published: (2004) -
Preliminary results of a Cancer Research UK phase I trial combining the dinitrobenzamide prodrug CB1954 (tretazicar) and the NQO2 substrate EP-0152R (caricotamide)
by: Sarker, D, et al.
Published: (2008)